Zimislecel is an investigational cell therapy designed to treat type 1 diabetes.
It consists of allogeneic insulin-producing cells that are transplanted into the liver of patients with type 1 diabetes.
Zimislecel aims to restore the body’s ability to produce insulin by replacing the insulin-producing cells (beta cells) that are destroyed in type 1 diabetes.
The transplanted cells function like natural beta cells, producing insulin in response to blood glucose levels.
Phase 1/2 clinical trials have shown promising results. In one trial, 10 out of 12 patients achieved insulin independence after receiving zimislecel.
It is well-tolerated, with most adverse events being mild or moderate.
Immunosuppression is required to prevent rejection of the transplanted cells, which can increase the risk of infections and other complications.